Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T12:05:38.079Z.
Calculation as of: 2026-10-06T12:05:38.079Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2c805ffacfcdae638738386c116dc6e6f159143ed75419b2c785d409d5d1ab78
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$21.90M
EBITDA Yield
N/A
TTM Avg
24.06%
3Y Avg
27.42%
5Y Avg
27.42%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $24.44M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.48M | N/A | 0.01% | 0.01% | 0.01% |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | N/A | 24.06% | 27.42% | 27.42% |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $18.82M | N/A | 2.57% | 2.17% | 2.17% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.65M | N/A | 392.49% | 233.09% | 233.09% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
